WHAT IS CLAIMED IS:

1. Use of eniluracil in the manufacture of a first medicament and use of capecitabine in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy for treating cancer in a human subject, wherein :

(a) eniluracil is to be orally administered at a dose of 30-60 mg/day to the subject;

(b) at least after 10 hours of step (a), capecitabine is to be orally administered

(i) at a fixed dose of 140-700 mg/day to the subject for 2 to 14 consecutive days or

(ii) at a dose providing a 5-FU exposure (AUC) of 1500 h*ng/mL or higher; and

(c) 3 to 14 days after step (b), the steps (a) and (b) are to be repeated.

2. The use of claim 1, wherein eniluracil is to be administered at 40 mg/day.

3. The use of claim 1, wherein capecitabine is to be administered at 160-500 mg/day.

4. The use of claim 1, wherein step (b) occurs at least after 17 hours of step (a).

5. The use of claim 1, wherein step (b) occurs 10-24 hours after step (a).

6. The use of claim 1, wherein step (c) occurs 7 days after step (b).

7. The use of claim 1, where the cancer is colorectal cancer, gastrointestinal tract tumor, breast cancer, pancreatic cancer, head and neck cancer, lung cancer, or advanced biliary tract cancer.